BRPI0809047B8 - composição, aditivo alimentar e métodos para tratar ou prevenir diabetes ou obesidade e para reduzir o índice glicêmico de um alimento contendo carboidrato - Google Patents
composição, aditivo alimentar e métodos para tratar ou prevenir diabetes ou obesidade e para reduzir o índice glicêmico de um alimento contendo carboidratoInfo
- Publication number
- BRPI0809047B8 BRPI0809047B8 BRPI0809047A BRPI0809047A BRPI0809047B8 BR PI0809047 B8 BRPI0809047 B8 BR PI0809047B8 BR PI0809047 A BRPI0809047 A BR PI0809047A BR PI0809047 A BRPI0809047 A BR PI0809047A BR PI0809047 B8 BRPI0809047 B8 BR PI0809047B8
- Authority
- BR
- Brazil
- Prior art keywords
- composition
- obesity
- carbohydrate
- methods
- food
- Prior art date
Links
- 206010012601 diabetes mellitus Diseases 0.000 title abstract 3
- 208000008589 Obesity Diseases 0.000 title abstract 2
- 150000001720 carbohydrates Chemical class 0.000 title abstract 2
- 239000002778 food additive Substances 0.000 title abstract 2
- 235000013373 food additive Nutrition 0.000 title abstract 2
- 230000002641 glycemic effect Effects 0.000 title abstract 2
- 235000020824 obesity Nutrition 0.000 title abstract 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 abstract 2
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 abstract 1
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 abstract 1
- IKMDFBPHZNJCSN-UHFFFAOYSA-N Myricetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC(O)=C(O)C(O)=C1 IKMDFBPHZNJCSN-UHFFFAOYSA-N 0.000 abstract 1
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 abstract 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 abstract 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 abstract 1
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 abstract 1
- 229940074393 chlorogenic acid Drugs 0.000 abstract 1
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 abstract 1
- 235000001368 chlorogenic acid Nutrition 0.000 abstract 1
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 abstract 1
- 208000030159 metabolic disease Diseases 0.000 abstract 1
- PCOBUQBNVYZTBU-UHFFFAOYSA-N myricetin Natural products OC1=C(O)C(O)=CC(C=2OC3=CC(O)=C(O)C(O)=C3C(=O)C=2)=C1 PCOBUQBNVYZTBU-UHFFFAOYSA-N 0.000 abstract 1
- 235000007743 myricetin Nutrition 0.000 abstract 1
- 229940116852 myricetin Drugs 0.000 abstract 1
- 235000005875 quercetin Nutrition 0.000 abstract 1
- 229960001285 quercetin Drugs 0.000 abstract 1
- 230000004580 weight loss Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Abstract
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US89548607P | 2007-03-19 | 2007-03-19 | |
US60/895,486 | 2007-03-19 | ||
PCT/US2008/056474 WO2008115723A1 (en) | 2007-03-19 | 2008-03-11 | Composition for treating diabetes and metabolic disorders with quercetin, myrcetin and chlorogenic acid |
Publications (3)
Publication Number | Publication Date |
---|---|
BRPI0809047A2 BRPI0809047A2 (pt) | 2014-09-02 |
BRPI0809047B1 BRPI0809047B1 (pt) | 2020-09-01 |
BRPI0809047B8 true BRPI0809047B8 (pt) | 2021-05-25 |
Family
ID=39590291
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0809047A BRPI0809047B8 (pt) | 2007-03-19 | 2008-03-11 | composição, aditivo alimentar e métodos para tratar ou prevenir diabetes ou obesidade e para reduzir o índice glicêmico de um alimento contendo carboidrato |
Country Status (8)
Country | Link |
---|---|
US (2) | US7943164B2 (pt) |
EP (1) | EP2129371B1 (pt) |
JP (1) | JP2010522185A (pt) |
CN (1) | CN101674821B (pt) |
BR (1) | BRPI0809047B8 (pt) |
CA (1) | CA2685031A1 (pt) |
MX (1) | MX2009009996A (pt) |
WO (1) | WO2008115723A1 (pt) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7943164B2 (en) * | 2007-03-19 | 2011-05-17 | Milton Joseph Ahrens | Composition and method for treating diabetes and metabolic disorders |
JP5524466B2 (ja) * | 2008-10-31 | 2014-06-18 | ユニテックフーズ株式会社 | 中性風味デザートベース |
US20100178413A1 (en) * | 2008-12-17 | 2010-07-15 | Mark Gorris | Food-based Supplement Delivery System |
US9918489B2 (en) * | 2008-12-17 | 2018-03-20 | Mark Gorris | Food-based supplement delivery system |
JP2011001311A (ja) * | 2009-06-19 | 2011-01-06 | Pola Chemical Industries Inc | 熱産生タンパク質発現促進剤 |
CN102469816A (zh) * | 2009-08-10 | 2012-05-23 | 斯托克里-丰康普公司 | 将类黄酮悬浮于饮料中的方法 |
CN102711522B (zh) | 2010-01-29 | 2015-09-09 | 雅培制药有限公司 | 包含hmb的无菌包装的营养液 |
EP2528459B1 (en) | 2010-01-29 | 2014-06-11 | Abbott Laboratories | Nutritional emulsions comprising calcium hmb |
US9693577B2 (en) | 2010-01-29 | 2017-07-04 | Abbott Laboratories | Method of preparing a nutritional powder comprising spray dried HMB |
TWI526161B (zh) | 2010-06-10 | 2016-03-21 | 亞培公司 | 包含鈣hmb及可溶性蛋白質之實質上透明營養液 |
US8372447B2 (en) * | 2010-08-03 | 2013-02-12 | Northern Innovations And Formulations Corp. | Compositions and methods for promoting weight loss and increasing energy |
WO2012097064A1 (en) * | 2011-01-13 | 2012-07-19 | Abbott Laboratories | Nutritional compositions and methods for controlling blood glucose |
WO2012114204A2 (en) | 2011-02-15 | 2012-08-30 | Ecole Polytechnique Federale De Lausanne (Epfl) Epfl-Tto | Methods of treating mitochondrial dysfunction |
WO2012168108A1 (en) | 2011-06-06 | 2012-12-13 | Unilever Plc | An edible composition |
JP2014521060A (ja) | 2011-06-28 | 2014-08-25 | コーニンクレッカ フィリップス エヌ ヴェ | 体液の検査用手段 |
CN102772424B (zh) * | 2012-06-13 | 2014-01-08 | 浙江大学 | 新橙皮苷在制备防治糖尿病药物中的应用 |
KR101396059B1 (ko) * | 2012-06-25 | 2014-05-16 | 중앙대학교 산학협력단 | 소귀나무잎으로부터 분리된 신규 황산염 페놀성 화합물 및 이의 항산화 및 항염 용도 |
US10079086B2 (en) | 2012-06-29 | 2018-09-18 | Koninklijke Philips N.V. | Processing of bound and unbound magnetic particles |
JP6291491B2 (ja) | 2012-06-29 | 2018-03-14 | コーニンクレッカ フィリップス エヌ ヴェKoninklijke Philips N.V. | 干渉粒子を含有する流体の処理 |
CN104471374B (zh) | 2012-07-18 | 2019-05-21 | 皇家飞利浦有限公司 | 对具有目标成分的样本流体进行处理 |
WO2014083474A1 (en) | 2012-11-30 | 2014-06-05 | Koninklijke Philips N.V. | Capture particle for selectively binding a target molecule |
JP6621463B2 (ja) | 2014-04-13 | 2019-12-18 | マルマル インベストメント エスピー.ゼット オー.オー. | 血糖値を低下させ、体重管理をするための健康食品組成物 |
CN106461656B (zh) | 2014-06-25 | 2020-03-24 | 皇家飞利浦有限公司 | 用于检测样品中的目标成分的生物传感器 |
EP3226882A4 (en) * | 2014-12-01 | 2018-07-11 | Cape Kingdom Nutraceuticals (Pty) Ltd. | Therapeutic compositions |
US10690663B2 (en) | 2015-03-26 | 2020-06-23 | Koninklijke Philips N.V. | Manufacturing of a biosensor cartridge |
CN105816473B (zh) * | 2015-07-06 | 2018-04-10 | 武汉华纳联合药业有限公司 | 一种黄酮苷类组合物及其制剂和制法 |
JP2017105745A (ja) * | 2015-12-02 | 2017-06-15 | 共栄化学工業株式会社 | 皮膚外用剤 |
US20180133243A1 (en) * | 2016-11-16 | 2018-05-17 | Holista Colltech Ltd | Method and composition for crude formulations of fortified sugar for glycemic control |
TWI667036B (zh) * | 2017-04-03 | 2019-08-01 | 大江生醫股份有限公司 | 植物萃取物於調控pdgfc、fgf2、igf1r、ptgis、nos3、edn1、plat、proc、vwf、f3、serpine1、il-8、icam1、vcam1及casp8基因的用途 |
US20220257561A1 (en) * | 2019-06-07 | 2022-08-18 | Advanced Delivery Labs Llc | Compositions and methods for improving wellness |
CN111387504A (zh) * | 2020-04-15 | 2020-07-10 | 武汉森澜生物科技有限公司 | 一种含绿原酸和柚皮苷的活性提取物、提取方法及其用途 |
WO2023192259A1 (en) * | 2022-03-28 | 2023-10-05 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Synergy for increasing insulin sensitivity |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3134233B2 (ja) * | 1991-07-26 | 2001-02-13 | 株式会社林原生物化学研究所 | α−グリコシル ケルセチンとその製造方法並びに用途 |
CA2284290A1 (en) * | 1997-03-20 | 1998-09-24 | Samuel Russell Vester | Nutritional supplement for cardiovascular health |
US7229651B2 (en) * | 1997-08-06 | 2007-06-12 | Melaleuca, Inc. | Dietary supplements containing natural ingredients |
KR20000019716A (ko) * | 1998-09-15 | 2000-04-15 | 박호군 | 바이오플라보노이드 화합물을 포함하는 혈당 강하용 조성물 |
US20020068704A1 (en) * | 1999-04-05 | 2002-06-06 | Ziegler Randy H. | Compositions and methods for treatment of diabetes |
WO2001080870A2 (en) * | 2000-04-13 | 2001-11-01 | Ocean Spray Cranberries, Inc. | Compositions derived from cranberry and grapefruit and therapeutic uses therefor |
US20030108627A1 (en) * | 2001-09-25 | 2003-06-12 | Jonathan Selzer | Cranberry based dietary supplement and dental hygiene product |
US20030133945A1 (en) * | 2002-01-11 | 2003-07-17 | Farley Michael Donald | Natural food supplement |
EP1559421B1 (en) * | 2002-11-06 | 2016-07-27 | Kao Corporation | Blood circulation promoting agent |
US7270837B2 (en) * | 2003-11-10 | 2007-09-18 | Rutgers, The State University Of New Jersey | Anti-inflammatory cranberry flavonol extract preparations |
US8017634B2 (en) * | 2003-12-29 | 2011-09-13 | President And Fellows Of Harvard College | Compositions for treating obesity and insulin resistance disorders |
WO2006024545A1 (en) * | 2004-09-03 | 2006-03-09 | Stichting Voor De Technische Wetenschappen | Fused bicyclic natural compounds and their use as inhibitors of parp and parp-mediated inflammatory processes |
US20060188590A1 (en) * | 2005-01-05 | 2006-08-24 | Mitsunori Ono | Compositions for treating diabetes or obesity |
US20070092454A1 (en) * | 2005-10-24 | 2007-04-26 | Colgate-Palmolive Company | Oral composition containing morin |
US7943164B2 (en) | 2007-03-19 | 2011-05-17 | Milton Joseph Ahrens | Composition and method for treating diabetes and metabolic disorders |
-
2008
- 2008-03-11 US US12/045,852 patent/US7943164B2/en active Active
- 2008-03-11 CN CN200880014120XA patent/CN101674821B/zh active Active
- 2008-03-11 EP EP08731870.5A patent/EP2129371B1/en active Active
- 2008-03-11 BR BRPI0809047A patent/BRPI0809047B8/pt not_active IP Right Cessation
- 2008-03-11 JP JP2009554635A patent/JP2010522185A/ja active Pending
- 2008-03-11 WO PCT/US2008/056474 patent/WO2008115723A1/en active Application Filing
- 2008-03-11 CA CA002685031A patent/CA2685031A1/en not_active Abandoned
- 2008-03-11 MX MX2009009996A patent/MX2009009996A/es active IP Right Grant
-
2011
- 2011-01-27 US US13/014,798 patent/US8198319B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
CN101674821A (zh) | 2010-03-17 |
BRPI0809047A2 (pt) | 2014-09-02 |
US8198319B2 (en) | 2012-06-12 |
EP2129371A1 (en) | 2009-12-09 |
WO2008115723A1 (en) | 2008-09-25 |
JP2010522185A (ja) | 2010-07-01 |
US20080234364A1 (en) | 2008-09-25 |
CA2685031A1 (en) | 2008-09-25 |
US7943164B2 (en) | 2011-05-17 |
CN101674821B (zh) | 2013-06-26 |
MX2009009996A (es) | 2010-01-20 |
BRPI0809047B1 (pt) | 2020-09-01 |
US20110118345A1 (en) | 2011-05-19 |
EP2129371B1 (en) | 2021-05-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0809047B8 (pt) | composição, aditivo alimentar e métodos para tratar ou prevenir diabetes ou obesidade e para reduzir o índice glicêmico de um alimento contendo carboidrato | |
EA200801897A1 (ru) | Ингибиторы mnk2 на основе 8-гетероарилпурина для лечения метаболических нарушений | |
EP2217596B8 (en) | Bicyclic heterocycle derivatives and their use as modulators of the activity of gpr119 | |
BR112013011249A2 (pt) | inibidores de ibat para tratamento de distúrbios metabólicos e condições relacionadas | |
CR10402A (es) | Inhibidores de 11-beta-hidroxiesteroide deshidrogenasa 1 | |
EP3318262A3 (en) | Composition for preventing or treating bone disease, obesity and lipid-related metabolic disease | |
PH12015502275B1 (en) | Therapuetic uses of empagliflozin | |
MY158994A (en) | Ampk modulators | |
EP3489360A3 (en) | Modulation of nuclear-retained rna | |
EA201201648A1 (ru) | Стимуляторы sgc | |
MY188457A (en) | Treatment of apolipoprotein-a1 related diseases by inhibition of natural antisense transcript to apolipoprotein-a1 | |
WO2010065792A3 (en) | Treatment of erythropoietin (epo) related diseases by inhibition of natural antisense transcript to epo | |
ECSP13012661A (es) | Composición farmacéutica, métodos de tratamiento y usos de la misma. | |
BR112012031873A2 (pt) | antagonistas de ciclo-hexil-azetidinila do ccr2 | |
GB201101459D0 (en) | Novel compounds and thier effects on fedding behaviour | |
MA33974B1 (fr) | Combinaisons d'un inhibiteur de pi3k et d'un inhibiteur de mek | |
WO2011083150A3 (en) | Obesity small molecules | |
BR112013011184A2 (pt) | composições e métodos para tratamento de mielofibrose | |
BRPI0914907A8 (pt) | Composição particulada para ração e ração | |
MX2020006720A (es) | Beta-caseina a2 y niveles de glucosa en sangre. | |
MX2013011124A (es) | Compuestos para el tratamiento del sindrome metabolico. | |
BR112012027648A2 (pt) | composto medicamento, método para profilaxia ou tratamento de doença, e, uso de composto | |
EA201591943A1 (ru) | Ингибиторы metap2 и способы лечения ожирения | |
BR112015022825A2 (pt) | métodos de diagnóstico, seleção e tratamento de doenças e condições causadas por ou associadas a metanógenos | |
BRPI0811881A8 (pt) | Condimento, alimento ou bebida, composição, e método para melhorar o sabor de um sal de potássio |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B15K | Others concerning applications: alteration of classification |
Ipc: A61K 31/353 (2006.01), A23L 33/105 (2016.01), A61K |
|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 01/09/2020, OBSERVADAS AS CONDICOES LEGAIS. |
|
B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 11/03/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |
|
B21F | Lapse acc. art. 78, item iv - on non-payment of the annual fees in time |
Free format text: REFERENTE A 16A ANUIDADE. |
|
B24J | Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12) |
Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2765 DE 02-01-2024 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |